Assembly Biosciences’ (ASMB) “Buy” Rating Reiterated at Guggenheim

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “buy” rating reaffirmed by investment analysts at Guggenheim in a research note issued to investors on Thursday,Benzinga reports. They presently have a $43.00 price objective on the biopharmaceutical company’s stock. Guggenheim’s target price points to a potential upside of 58.53% from the stock’s previous close.

ASMB has been the subject of a number of other reports. Wall Street Zen lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a report on Monday, May 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Assembly Biosciences Stock Performance

ASMB stock opened at $27.13 on Thursday. Assembly Biosciences has a 1 year low of $13.70 and a 1 year high of $39.71. The stock has a market capitalization of $431.10 million, a price-to-earnings ratio of -246.52 and a beta of 1.08. The stock’s fifty day moving average is $28.57 and its two-hundred day moving average is $30.40.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The business had revenue of $8.21 million during the quarter, compared to analyst estimates of $9.27 million. As a group, analysts predict that Assembly Biosciences will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

Several hedge funds have recently made changes to their positions in ASMB. Bank of America Corp DE raised its holdings in shares of Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in Assembly Biosciences during the fourth quarter worth approximately $147,000. Charles Schwab Investment Management Inc. acquired a new position in Assembly Biosciences in the fourth quarter worth approximately $228,000. Virtus Investment Advisers LLC acquired a new position in Assembly Biosciences in the fourth quarter worth approximately $251,000. Finally, Engineers Gate Manager LP bought a new position in shares of Assembly Biosciences in the fourth quarter valued at $353,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.